DaVita Clinical Research Presents Research Results at the American Nephrology Nurses Association National Symposium
April 22 2013 - 8:00AM
Business Wire
DaVita Clinical Research® (DCR®) (NYSE: DVA), a specialty
contract research organization with services spanning the full
spectrum of drug and device development, today announced that
company representatives will present four abstracts at the American
Nephrology Nurses Association (ANNA) National Symposium scheduled
for April 21-24, 2013 in Las Vegas, Nevada.
With a membership of more than 10,000 registered nurses and
other health care professionals, the mission of ANNA is to promote
excellence in nephrology nursing and appreciation of the profession
in order to make a positive difference for people with kidney
disease.
Researchers from DaVita®, the dialysis division of DaVita
Healthcare Partners Inc., and DCR will present results from a
number of innovative clinical improvement programs originating from
DaVita and its research partners.
“At DaVita, we’re committed to furthering education and
improving clinical outcomes, which we feel is reflected in our
studies,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N.,
vice president of clinical research at DaVita. “It’s ideal to
present these findings at ANNA, where health care professionals
collaborate on ways to improve the quality of life for kidney
patients.”
At this year's ANNA meeting, researchers from DCR and DaVita
will focus on several key research initiatives in end-stage renal
disease, including:
- “Decreasing Peritonitis Rate in
Peritoneal Dialysis Resulting in Lower Mortality and Technique
Failure” Oral presentation by Tracey Milligan, DaVita regional
operations director, on Monday, April 22, in Abstract Concurrent
Session #161, from 5:40 p.m. – 5:55 p.m.
- “Extracellular Volume Control in
Dialysis Patients to Reduce Hospitalizations.” Oral presentation by
Irina Goykhman, vice president of clinical improvement at DaVita,
on Monday, April 22, in Abstract Concurrent Session #162, from 5:20
p.m. – 5:35 p.m.
- “Hemoglobin Trends in Incident
End-Stage Renal Disease Patients from 2008-2012” Poster
presentation by Deuzimar Kulawik, director, office of the
chief medical officer at DaVita
- “Implementation of
Electrolytically-Produced Sodium Hypochlorite Protocol Improved
Peritonitis Rates” Poster presentation by Tracey Milligan
DCR provides a collaborative bridge between DaVita’s health care
community and the academic, pharmaceutical and biotech research
community. DCR and DaVita share a dedication to improving the
health and quality of life for kidney care patients.
To learn more about DCR and upcoming clinical trials, please
visit www.ParticipateDaVita.com.
DaVita, DaVita Clinical Research, DCR and DaVita HealthCare
Partners are trademarks or registered trademarks of DaVita
Healthcare Partners Inc. All other trademarks are the property of
their respective owners.
About DaVita
DaVita is the dialysis division of DaVita HealthCare Partners
Inc., a Fortune 500® company that, through its operating divisions,
provides a variety of health care services to patient populations
throughout the United States and abroad. A leading provider of
kidney care in the United States, DaVita delivers dialysis services
to patients with chronic kidney failure and end stage renal
disease. DaVita strives to improve patients’ quality of life by
innovating clinical care, and by offering integrated treatment
plans, personalized care teams and convenient health-management
services. As of Dec.31, 2012, DaVita operated or provided
administrative services at 1,954 outpatient dialysis centers
located in the United States serving approximately 153,000
patients. The company also operated 36 outpatient dialysis centers
located in eight countries outside the United States. DaVita
supports numerous programs dedicated to creating positive,
sustainable change in communities around the world. The company’s
leadership development initiatives and social responsibility
efforts have been recognized by Fortune, Modern Healthcare,
Newsweek and WorldBlu. For more information, please visit
DaVita.com.
About DaVita Clinical Research
DaVita Clinical Research (DCR), a wholly owned subsidiary
of DaVita HealthCare Partners Inc., uses its extensive,
applied database and real-world healthcare experience to assist
pharmaceutical and medical device companies in the design,
recruitment, and completion of clinical trials including
retrospective and prospective pragmatic trials. DCR’s
scientific and clinical expertise spans the lifecycle of product
development with more than 150 client companies.
DCR’s Biorepository, Early Clinical Research unit
(Phase I-IIa) and Clinical Development (Phase IIb through
post-marketing) network of physicians and investigative sites,
data research, Health Economics & Outcomes
Research, Central Laboratory, and Medical
Communications are focused on providing world-class research
in both complex/specialty populations and therapeutic areas, and
especially in CKD and ESRD populations. To learn more about DCR,
visit www.davitaclinicalresearch.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From Jul 2024 to Aug 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Aug 2023 to Aug 2024